Pharming Group N.V.

6 months ago · seekingalpha.com

Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript

8 months ago · seekingalpha.com

Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript

9 months ago · seekingalpha.com

Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company. PHAR delivered $376M in FY2025 revenue, up 27% YoY, surpassing guidance, and generated $44M in operating cash flow, supporting financial independence. Key near-term catalysts include FDA approval for Joenja's pediatric label and pivotal data from leniolisib and KL1333 clinical programs.

9 months ago · seekingalpha.com

Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript

9 months ago · investors.com

Biotech stock Pharming was pummeled Monday after the FDA rejected the company's request to expand the patient pool for Joenja.

9 months ago · globenewswire.com

Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. The FDA raised an issue with the potential for underexposure in lower weight pediatric patients.